TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Science

    OncoPharm

    OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

    Advertise

    Copyright: © All rights reserved

    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Emend's Emergence Mar 25, 2021
    Show notes

    The Landmarks of OncoPharm series returns to discuss 2 pivotal trials that ushered in the age of aprepitant and NK-1 receptor anagonists for CINV. Aprepitant in HEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2003.01.095 Aprepitant in MEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2005.09.050

    Tivozanib (and More) Mar 18, 2021
    Show notes

    Tivozanib's FDA approval for mRCC was a long time in the making, but what is its role? Disappointing atezolizumab results for adjuvant treatment of bladder cancer (IMvigor-010). Preliminary data on antibody responses to COVID-19 vaccination in cancer patients.

    Indolent Lymphoma Week Mar 12, 2021
    Show notes

    This week, two indolent lymphoma updates: 1. CAR-T (Axl-Cel) for follicular lymphoma 2. Is there a preferred platinum salt in DHAP for Mantle cell lymphoma* patients heading to transplant? (https://pubmed.ncbi.nlm.nih.gov/33658645/) *Yes, I know - not really an indolent lymphoma in this case.

    Melphalan Flufenamide Mar 04, 2021
    Show notes

    Melphalan flufenamide, a drug that makes tumor cell kinetics cool again, is our main topic. Also, brief updates on lorlatinib (ALK+ mNSCLC) and nivolumab/cabozantinib (mRCC).

    Trilaciclib, Cemiplimab & GU Updates Feb 25, 2021
    Show notes

    Topics covered: 1. Trilaciclib's approval to minimize bone marrow suppression 2. Cemiplimab's approval for mNSLC with high PD-L1 expression 3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma 4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer 5. More of the same with lenvatinib + pembrolizumab in mRCC

    Filgrastim Turns 30 Feb 18, 2021
    Show notes

    Happy Birthday to a drug that ushered in its own era! We discuss its history and development and just a little bit about its benefit, role, and a few clinical pearls.

    Umbralisib Feb 11, 2021
    Show notes

    Discussing the latest TKI approval, umbralisib, and its familiar toxicity profile. Also, a few final words on a new CAR-T product and a cemiplimab expanded approval.

    Tepotinib Feb 04, 2021
    Show notes

    In light of teptinib's recent FDA-approval for exon-14 skipping MET altered metastatic NSLCC, we compare tepotinib to its predecessor in this space - capmatinib.

    Updates on mRCC and COVID-19 Vaccination Jan 28, 2021
    Show notes

    With the recent FDA-approval of nivolumab + cabozantinib for metastatic renal cell carcinoma (mRCC, we review Checkmate-9ER results and how they compare to other combination treatments in mRCC. We then end by discussion preliminary recommendations on vaccinating patients with cancer agains COVID-19. Checkmate-9ER abstract: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-cabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-renal-cell-carcinoma-first-results-from-the-randomized-phase-iii-checkmate-9er-trial

    Updates T-DXd (gastric) & SC Dara (AL Amyloidosis) Jan 21, 2021
    Show notes

    Discussing recent FDA approvals for expanded indications for trastuzumab-deruxtecan for gastric cancer (based on DESTINY-Gastric01) and SC daratumumab for AL amyloidosis. DESTINY-Gastric01: https://www.nejm.org/doi/full/10.1056/NEJMoa2004413

    Previous 1 26 27 28 29 30 45 Next

    Related Podcasts

    Invisibilia

    1

    Invisibilia Personal Journals
    Hidden Brain – Hidden Brain, Shankar Vedantam

    2

    Hidden Brain – Hidden Brain, Shankar Vedantam Science
    How To Do Everything

    3

    How To Do Everything Science
    Hidden Brain

    4

    Hidden Brain Games & Hobbies
    Something You Should Know

    5

    Something You Should Know Education
    Sword and Scale – Sword and Scale

    6

    Sword and Scale – Sword and Scale Alternative Health
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights